Update for Investors of

CIPLA

is currently trading at Rs. 1583.00, up by 3.15 points or 0.20% from its previous closing of Rs. 1579.85 on the BSE. The scrip opened at Rs. 1590.00 and has touched a high and low of Rs. 1590.00 and Rs. 1568.25 respectively. So far 85765 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1702.00 on 09-Oct-2024 and a 52 week low of Rs. 1310.05 on 07-Apr-2025. Last one week high and low of the scrip stood at Rs. 1607.55 and Rs. 1526.90 respectively. The current market cap of the company is Rs. 127786.69 crore. The promoters holding in the company stood at 29.19%, while Institutions and Non-Institutions held 54.49% and 16.31% respectively. Cipla’s arm -- Cipla USA, Inc. is recalling over 20,000 packs of Ibuterol Sulfate Inhalation Aerosol. Albuterol is used to treat or prevent bronchospasm in patients with asthma, bronchitis, emphysema, and other lung diseases. The company is recalling 20,352 packs of the inhalation drug due to Failed Stability Specifications. Out-of-specification results were observed in Induction Port during the analysis of Particle size distribution at the 12-month time point. New Jersey-based Cipla USA, Inc. initiated the Class III recall on July 24 this year. As per the USFDA, a Class III recall is initiated in a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences. Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.